TY - JOUR
T1 - Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.
AU - Douglas, Genevieve
AU - Harrison, Claire
AU - Forsyth, Cecily
AU - Bennett, Michael
AU - Stevenson, William
AU - Hounsell, John
AU - Ratnasingam, Sumita
AU - Ritchie, David
AU - Ross, David
AU - Grigg, Andrew
PY - 2017/1/2
Y1 - 2017/1/2
N2 - Hydroxyurea (Hu) is widely used as first-line cytoreductive therapy for patients with high-risk Philadelphia-negative myeloproliferative neoplasms (Ph-neg MPN), but a small proportion of patients have refractory disease or experience adverse effects. Studies have demonstrated busulfan (Bu) to be an active first-line agent, but data on its role as second-line or later therapy are minimal. To evaluate its efficacy and safety in this context, we undertook a multicenter audit of Ph-neg MPN patients who had received Bu as therapy for Hu intolerance or failure. Of 51 patients identified, 38 (75%) achieved either complete or partial hematological response following at least one Bu cycle. Bu was generally well tolerated, with only 21/135 (15%) cycles complicated by adverse effects, predominantly cytopenia; only 6% of cycles were ceased due to treatment complications. Bu is an effective and well-tolerated agent in patients with Ph-neg MPN in the setting of Hu intolerance or unresponsiveness.
AB - Hydroxyurea (Hu) is widely used as first-line cytoreductive therapy for patients with high-risk Philadelphia-negative myeloproliferative neoplasms (Ph-neg MPN), but a small proportion of patients have refractory disease or experience adverse effects. Studies have demonstrated busulfan (Bu) to be an active first-line agent, but data on its role as second-line or later therapy are minimal. To evaluate its efficacy and safety in this context, we undertook a multicenter audit of Ph-neg MPN patients who had received Bu as therapy for Hu intolerance or failure. Of 51 patients identified, 38 (75%) achieved either complete or partial hematological response following at least one Bu cycle. Bu was generally well tolerated, with only 21/135 (15%) cycles complicated by adverse effects, predominantly cytopenia; only 6% of cycles were ceased due to treatment complications. Bu is an effective and well-tolerated agent in patients with Ph-neg MPN in the setting of Hu intolerance or unresponsiveness.
KW - busulfan
KW - hydroxyurea
KW - Philadelphia-negative myeloproliferative neoplasms
UR - http://www.scopus.com/inward/record.url?scp=84979516748&partnerID=8YFLogxK
U2 - 10.1080/10428194.2016.1187269
DO - 10.1080/10428194.2016.1187269
M3 - Article
SN - 1042-8194
VL - 58
SP - 89
EP - 95
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 1
ER -